

Clerk of the House of Representatives  
Legislative Resource Center  
B-106 Cannon Building  
Washington, DC 20515

Secretary of the Senate  
Office of Public Records  
232 Hart Building  
Washington, DC 20510

SECRETARY OF THE SENATE

05 FEB 23 AM 10:42

**LOBBYING REPORT**

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant name			
Organization	Hoffmann-La Roche Inc.		
2. Address <input type="checkbox"/> Check if different than previously reported			
Address	1425 K Street NW, Suite 650		
City	Washington	State	DC
		Zip Code	20005
		Country	
3. Principal place of business (if different than line 2)			
City	Nutley	State	NJ
		Zip Code	07110
		Country	
4a. Contact Name		b. Telephone number	c. E-mail
Prefix	Full Name		
Ms.	Candace Sams	202-408-0090	candace.sams@roche.com
7. Client Name <input checked="" type="checkbox"/> Self		5. Senate ID #	
Hoffmann-La Roche Inc.		18411	
		6. House ID #	
		311670	

**TYPE OF REPORT** 8. Year 2004 Midyear (January 1-June 30) ☐ OR Year End (July 1-December 31) ☐

9. Check if this filing amends a previously filed version of this report ☐

10. Check if this is a Termination Report ☐ ⇒ Termination Date                     

11. No Lobbying Act ☐

**INCOME OR EXPENSES - Complete Either Line 12 OR Line 13****12. Lobbying Firms**

INCOME relating to lobbying activities for this reporting period was:

Less than \$10,000 ☐

\$10,000 or more ☒ ⇒ \$                     

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

**13. Organizations**

EXPENSES relating to lobbying activities for this reporting period were:

Less than \$10,000 ☐

\$10,000 or more ☒ ⇒ \$ 1,478,873

**14. REPORTING METHOD.** Check box to indicate expected accounting method. See instructions for description of options.

- ☐ **Method A.** Reporting amounts using LDA definitions of lobbying.
- ☐ **Method B.** Reporting amounts under section 6033(b)(8), Internal Revenue Code.
- ☐ **Method C.** Reporting amounts under section 162(e) of the Internal Revenue Code.

**Form Co**

Printed Name and Title Michael J. Eging Executive Director, Public Policy and Federal Government Affairs

LD-2DS (Rev. 4/03)

*Michael J. Eging* 2/14/05

Page 1 of 9

Registrant Name Hoffmann-La Roche Inc.Client Name Hoffmann-La Roche Inc.

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each** information as requested. Attach additional page(s) as needed.

15. General issue area code CPT - Copyright/Patent/Trademark (one per page)

16. Specific lobbying issues

*Add page to continue specific issues description for this issue*

S.812--Greater Access to Affordable Pharmaceuticals Act of 2001


17. House(s) of Congress and Federal agencies contacted ☐ Check if None

United States House of Representatives  
United States Senate

18. Name of each individual who acted as a lobbyist in this issue area *Add a page to continue adding lobbyists for*

First Name	Name Last Name	Suffix	Covered Official Position (if applicable)
Michael	Eging		Executive Director, Federal Government Affairs
Kelli	Mills		Assistant Director, Federal Government Affairs
David	Nichols		Director, Federal Government Affairs

19. Interest of each foreign entity in the specific issues listed on line 16 above ☐ Check if None

 2/14/05

Add a page for a differ

Printed Name and Title Michael J. Eging, Executive Director, Public Policy and Federal Government Aff:

LD-2DS (REV/03)

Page 2 of

Registrant Name Hoffmann-La Roche Inc.Client Name Hoffmann-La Roche Inc.

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each information as requested. Attach additional page(s) as needed.

15. General issue area code HCR--Health Issues (one per page)

16. Specific lobbying issues

S.1931, Amend Title XVIII of Social Security Act to Improve Patient Access to and Utilization of Colorectal Cancer Screening Benefit Under Medicare Program.  
 S.193, Access to Cancer Therapies Act  
 S.847, Early Treatment for HIV Act of 2003  
 S.1143, Hepatitis C Epidemic Control and Prevention Act  
 S.2729, Amend Title XVIII of Social Security Act to provide for a Medicare voluntary prescription drug deli

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

United States House of Representatives  
 United States Senate

18. Name of each individual who acted as a lobbyist in this issue area *Add a page to continue adding lobbyists for*

First Name	Name Last Name	Suffix	Covered Official Position (if applicable)
Michael	Eging		Executive Director, Federal Government Affairs
Kelli	Mills		Assistant Director, Federal Government Affairs
David	Nichols		Director, Federal Government Affairs

19. Interest of each foreign entity in the specific issues listed on line 16 above ☐ Check if None

*Michael J. Eging* 2/14/05

Add a page for a different

Printed Name and Title

Michael J. Eging, Executive Director, Public Policy and Federal Government Affa

FD-205 (REV. 03)

Page 3 of 0

Registrant Name Hoffmann-La Roche Inc.Client Name Hoffmann-La Roche Inc.

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each information as requested. Attach additional page(s) as needed.

15. General issue area code HCR - Health Issues (one per page)

16. Specific lobbying issues

S.2766, Making appropriations for the Departments of Labor, HHS & Education  
 S.987, To amend Title XIX of Social Security Act to permit States the option to provide Medicaid coverage for HIV  
 S.1976, Provide for a comprehensive federal effort relating to treatments for and prevention of cancer  
 S.710, To require coverage for colorectal cancer screenings

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

United States House of Representatives  
 United States Senate

18. Name of each individual who acted as a lobbyist in this issue area *Add a page to continue adding lobbyists if*

Name			Covered Official Position (if applicable)
First Name	Last Name	Suffix	
Michael	Eging		Executive Director, Federal Government Affairs
Kelli	Mills		Assistant Director, Federal Government Affairs
David	Nichols		Director, Federal Government Affairs

19. Interest of each foreign entity in the specific issues listed on line 16 above ☐ Check if None

 2/14/05

Add a page for a diffe

Printed Name and Title Michael J. Eging, Executive Director, Public Policy and Federal Government Aff

LD-2DS (REV/03)

Page 4 of 9



Registrant Name Hoffmann-La Roche Inc.Client Name Hoffmann-La Roche Inc.

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each information as requested. Attach additional page(s) as needed.

15. General issue area code HCR - Health Issues (one per page)

16. Specific lobbying issues

Lobbied to support increases in the FY 2004 Labor/Health and Human Services/Education Appropriations bill for enhanced access to HIV therapies under the Ryan White CARE Act.  
Lobbied to oppose VA Standardization of Glucose Testing equipment.  
Lobbied to support Veterans Administration HUD Appropriations Bill  
Lobbied to support BSE Test Approval

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

United States House of Representatives  
United States Senate  
Veterans Administration  
U.S. Department of Agriculture

18. Name of each individual who acted as a lobbyist in this issue area *Add a page to continue adding lobbyists to*

Name			Covered Official Position (if applicable)
First Name	Last Name	Suffix	
Michael	Eging		Executive Director, Federal Government Affairs
Kelli	Mills		Assistant Director, Federal Government Affairs
David	Nichols		Director, Federal Government Affairs

19. Interest of each foreign entity in the specific issues listed on line 16 above ☐ Check if None



2/14/05

Add a page for a differ

Printed Name and Title Michael J. Eging, Executive Director, Public Policy and Federal Government Aff

INDS (REL/03)

Page 5 of 9

Registrant Name Hoffmann-La Roche Inc.Client Name Hoffmann-La Roche Inc.

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each information as requested. Attach additional page(s) as needed.

15. General issue area code MMM Medicare/Medicaid (one per page)

16. Specific lobbying issues

HR 1641, Medicaid Obesity Treatment Act  
 S.2625, Amend Title XVIII of Social Security Act to Provide Coverage of Outpatient Prescription Drugs under the Medicare Program  
 HR 4860, Amend Title XVIII of Social Security Act to Provide Voluntary Program for Prescription Drug Coverage Under Medicare  
 HR 1839, Immunosuppressives Drug Coverage Act

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

United States House of Representatives  
 United States Senate

18. Name of each individual who acted as a lobbyist in this issue area *Add a page to continue adding lobbyists for*

Name			Covered Official Position (if applicable)
First Name	Last Name	Suffix	
Michael	Eging		Executive Director, Federal Government Affairs
Kelli	Mills		Assistant Director, Federal Government Affairs
David	Nichols		Director, Federal Government Affairs

19. Interest of each foreign entity in the specific issues listed on line 16 above ☐ Check if None



2/14/05

Add a page for a differ

Printed Name and Title Michael J. Eging, Executive Director, Public Policy and Federal Government Aff.

LD-7DS (REV 03)

Page 6 of 9

Registrant Name Hoffmann-La Roche Inc.Client Name Hoffmann-La Roche Inc.

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each c information as requested. Attach additional page(s) as needed.

15. General issue area code MMM - Medicare/Medicaid (one per page)

16. Specific lobbying issues

S. 880, Immunosuppressive Drug Coverage Act  
 HR. 3032, Medicare Coverage of Immunosuppressives Drug Coverage  
 S. 1204, Comprehensive Immunosuppressive Drug Coverage Act  
 S. 358, Medicare Prescription Drug and Modernization Act  
 Lobbied to support Don Dümoulin appt on CMS Advisory Committee  
 Meeting with Tim Trysla, CMS to discuss reimbursement for HCV


17. House(s) of Congress and Federal agencies contacted ☐ Check if None

United States House of Representatives  
 United States Senate

18. Name of each individual who acted as a lobbyist in this issue area *Add a page to continue adding lobbyists fo*

Name			Covered Official Position (if applicable)
First Name	Last Name	Suffix	
Michael	Eging		Executive Director, Federal Government Affairs
Kelli	Mills		Assistant Director, Federal Government Affairs
David	Nichols		Director, Federal Government Affairs

19. Interest of each foreign entity in the specific issues listed on line 16 above ☐ Check if None

 2/14/05

Add a page for a differ

Printed Name and Title Michael J. Eging, Executive Director, Public Policy and Federal Government Aff:

LD-2DS (RE/03)

Page 7 of 9

Registrant Name Hoffmann-La Roche Inc.Client Name Hoffmann-La Roche Inc.

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each information as requested. Attach additional page(s) as needed.

15. General issue area code MMM - Medicare/Medicaid (one per page)

16. Specific lobbying issues

Lobbied to support increase in HCV payment rate
---

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

United States House of Representatives
United States Senate

18. Name of each individual who acted as a lobbyist in this issue area *Add a page to continue adding lobbyists fo*

Name			Covered Official Position (if applicable)
First Name	Last Name	Suffix	
Michael	Eging		Executive Director, Federal Government Affairs
Kelli	Mills		Assistant Director, Federal Government Affairs
David	Nichols		Director, Federal Government Affairs

19. Interest of each foreign entity in the specific issues listed on line 16 above ☐ Check if None

--

 2/14/05

Add a page for a differ

Printed Name and Title Michael J. Eging, Executive Director, Public Policy and Federal Government Affa

LD-2DS (RE/03)

Page 8 of



Registrant Name Hoffmann-La Roche Inc.Client Name Hoffmann-La Roche Inc.**Information Update Page - Complete ONLY where registration information has changed.****20. Client new address**

Address

City

State

Zip Code

Country

**21. Client new principal place of business (if different than line 20)**

City

State

Zip Code

Country

**22. New general description of client's business or activities****LOBBYIST UPDATE****23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client**

	First Name	Last Name	Suffix		First Name	Last Name
1				3		
2				4		

**ISSUE UPDATE****24. General lobbying issues that no longer pertain**

Find the code to select below

**AFFILIATED ORGANIZATIONS****25. Add the following affiliated organization(s)**

Name	Address	Principal place of Business (city and state or country)
	Address	City
	C/S/Z	State
	Address	City
	C/S/Z	State

**26. Name of each previously reported organization that is no longer affiliated with the registrant or client**

1		2		3	
---	--	---	--	---	--

**FOREIGN ENTITIES****27. Add the following foreign entities**

Name	Address	Principal place of business (city and state or country)	Amount of contribution for lobbying activities	Over per cie
	Street Address	City		
	City	State/Province		
		Country		
		State		
		Country		

**28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, affiliated organization**

1		3		5	
2		4		6	

Printed Name and Title

Michael J. Eging, Executive Director, Public Policy and Federal Government Aff

LD-2DS (RE)/03 )

*Michael J. Eging* 2/14/05

Page 9 of 9